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Abstract 
As part of its Single Technology Appraisal (STA) process, the UK National Institute for Health and 
Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the 
clinical effectiveness and cost-effectiveness of ibrutinib for treating :DOGHQVWU|P¶V
macroglobulinaemia (WM). The School of Health and Related Research Technology Assessment 
Group at the University of Sheffield was commissioned to act as the independent Evidence Review 
Group (ERG). The ERG produced a critical review of the evidence for the clinical effectiveness and 
cost-effectiveness of ibrutinib based on the company's submission to NICE. The clinical evidence was 
derived from one Phase II, single-arm, open-label study of ibrutinib in adult patients with WM who had 
received at least one prior therapy (Study 1118E) and an indirect comparison using a matched cohort 
from a retrospective European Chart Review of patients receiving various treatments for WM. The 
indirect comparison suggested a hazard ratio for progression-free survival (PFS) of 0.25 (95% 
confidence interval 0.11 to 0.57). The ERG had concerns regarding the high risk of bias in Study 1118E, 
the limited generalisability of the study and the absence of RCT evidence7KHFRPSDQ\¶V0DUNRY
model assessed the cost-effectiveness of ibrutinib versus rituximab/chemotherapy for patients with 
relapsed/refractory (R/R) WM from the perspective of the National Health Service (NHS) and Personal 
Social Services (PSS) over a lifetime horizon. Based on the FRPSDQ\¶Voriginal Patient Access Scheme 
(PAS)WKHFRPSDQ\¶s probabilistic model generated an incremental cost-effectiveness ratio (ICER) for 
ibrutinib versus rituximab/chemotherapy of £58,905 per quality-adjusted life-year (QALY) gained. 
Following a critique of the model, the ERG's preferred analysis, which corrected cost errors and used 
the observed mortality rate from Study 1118E, generated a probabilistic ICER of £61,219 per QALY 
gained; based on this amended model, additional exploratory analyses produced ICERs for ibrutinib 
which were greater than £60,000 per QALY gained. Subsequently, the company offered to provide 
ibrutinib at a price that resulted in ibrutinib being cost-effective within the Cancer Drugs Fund (CDF). 
The Committee recommended ibrutinib for use in the CDF as an option for treating WM in adults who 
have had at least one prior therapy, only if the conditions in the managed access agreement for ibrutinib 
are followed. 
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Key messages for decision-makers 
x The main clinical evidence for ibrutinib was Study 1118E ± a single-arm, open-label study of 
ibrutinib in adult patients with :DOGHQVWU|P¶VPDFURJOREXOLQDHPLD (WM) who had received at 
least one prior therapy, and an indirect comparison using a matched cohort from a retrospective 
European Chart Review of patients receiving various treatments for WM. The indirect 
comparison suggested a hazard ratio (HR) for progression-free survival (PFS) of 0.25 (95% 
confidence interval 0.11 to 0.57). No comparative analysis was undertaken for survival 
outcomes. 
x The main issues identified by the ERG included: (i) the high risk of bias in Study 1118E; (ii) 
concerns regarding the generalisability of Study 1118E; (iii) the absence of RCT evidence; (iv) 
XQFHUWDLQW\ VXUURXQGLQJ WKH FRPSDQ\¶V LQGLUHFW comparison for PFS; (v) the absence of an 
indirect comparison of overall survival and (vi) concerns regarding the structure of the 
FRPSDQ\¶VPRGHODQGWKHHYLGHQFHXVHGWRLQIRUPLWVSDUDPHWHUV 
x Additional analyses undertaken by the ERG suggested that the incremental cost-effectiveness 
ratio (ICER) for ibrutinib versus rituximab/chemotherapy was expected to be greater than 
£60,000 per quality-adjusted life year (QALY) gained (using the original Patient Access 
Scheme [PAS]). The (5*¶VDQDO\VHVVKRZHGWKDWHYen under favourable assumptions, varying 
the HR for PFS between 0.01 and 1.00 produced ICERs for ibrutinib versus 
rituximab/chemotherapy of at least £56,917 per QALY gained. 
x Based on additional analyses and an updated PAS, the appraisal committee concluded that the 
most plausible ICER was likely to be at least £54,100 per QALY gained. The company 
subsequently offered an improved value proposition for ibrutinib for use in the Cancer Drugs 
Fund (CDF). 
x Ibrutinib was recommended, within its marketing authorisation, for use in the CDF as an option 
for treating WM in adults who have had at least one prior therapy, only if the conditions in the 
managed access agreement for ibrutinib are followed. 
  
4 
 
1. INTRODUCTION 
Health technologies must be shown to be clinically effective and to represent a cost-effective use of 
resources to be recommended for use within the National Health Service (NHS) in England. The 
National Institute for Health and Care Excellence (NICE) is an independent organisation responsible 
for providing national guidance on promoting good health, and preventing and treating ill health, in 
priority areas with significant impact. The NICE Single Technology Appraisal (STA) process usually 
covers new technologies soon after they have received UK marketing authorisation and is specifically 
designed for the appraisal of a single health technology within a single indication [1]. Within the STA 
process, the manufacturer of a technology provides NICE with a written submission containing relevant 
clinical effectiveness evidence alongside a health economic model that summarises the FRPSDQ\¶V
estimates of the cost-effectiveness of the technology. The Evidence Review Group (ERG), an external 
academic organisation which is independent of NICE, reviews the submission with advice from clinical 
specialists and produces an ERG report. The NICE appraisal committee $&FRQVLGHUVWKHFRPSDQ\¶V 
submission (CS), the ERG report, and testimony from experts and other stakeholders and formulates 
preliminary guidance - the appraisal consultation document (ACD) - which indicates the initial decision 
of the AC regarding the recommendation (or not) of the intervention. Stakeholders are subsequently 
invited to comment on the submitted evidence and the ACD, after which an ACD may be produced or 
a final appraisal determination (FAD) issued, which is open to appeal. An ACD is not produced when 
the intervention is recommended without restriction; in such instances, a FAD is produced directly. This 
paper presents a summary of the ERG report [2] produced by the School of Health and Related Research 
Technology Assessment Group at the University of Sheffield and the NICE FAD [3] for the STA of 
LEUXWLQLEIRUWKHWUHDWPHQWRI:DOGHQVWU|P¶VPDFURJOREXOLQDHPLD (WM). It also covers the subsequent 
development of the NICE guidance for the use of this drug in England [4]. Full details of all relevant 
appraisal documents can be found on the NICE website [5]. 
 
2. DECISION PROBLEM 
WM is an incurable lymphoproliferative B-cell disorder characterised by infiltration of 
lymphoplasmacytic cells into the bone marrow and immunoglobulin M (IgM) monoclonal gammopathy 
[6]. WM is considered to be a lymphoplasmacytic lymphoma (LPL) by both the Revised European 
American Lymphoma (REAL) and World Health Organization (WHO) classification systems. WM is 
rare and accounts for less than 2% of all non-+RGJNLQ¶V/\PSKRPDV1+/V [6]. Current estimates 
from the British Committee for Standards in Haematology (BCSH) suggest an incidence rate for WM 
of 0.55 per 100,000 people per year in the UK, which corresponds to approximately 292 new cases in 
England each year. 
 
Diagnosis requires demonstration of an IgM monoclonal protein and histological evidence of bone 
marrow infiltration by lymphoplasmacytic cells. Several factors are associated with poor prognosis, 
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including: (i) advanced age (>\HDUV LL ȕ-microglobulin >3mg/L; (iii) anaemia (haemoglobin 
JG/WKURPERF\WRSHQLDSODWHOHWFRXQW[/DQGLY,J0PRQRFORQDOJDPPRSDWK\
(IgM >7.0g/dL) [6]. Based on the International Prognostic Scoring System for WM (IPSSWM) for 
newly diagnosed patients, median survival is estimated to be 11.88 years for low-risk patients, 8.22 
years for intermediate-risk patients and 3.63 years for high-risk patients [7]. 
 
Clinical manifestations of WM include cytopenias (anaemia) and lymphadenomegaly resulting from 
infiltration by lymphoplasmacytic cells and IgM paraprotein-related symptoms such as: 
cryoglobulinemia; cold agglutinin syndrome; demyelinating neuropathy; amyloidosis (involving 
kidneys, the heart and the nervous system); infections, and; symptomatic hyperviscosity (visual 
disturbance, headache, dizziness, altered consciousness, fatigue and weakness) [6]. There is no evidence 
relating to the impact of WM and its treatment on health-related quality of life (HRQoL); unpublished 
patient survey data suggest that the symptoms which impact most on SDWLHQWV¶+54R/ are: tiredness or 
lack of energy; weakness; frequent infections; tingling or numbness in the feet or legs and shortness of 
breath [8]. 
 
2.1 Current treatment 
There is currently no licensed treatment that represents the standard of care for WM. Taking into 
account the fitness of the patient, standard treatment is typically based on treatment options developed 
for other lymphoproliferative diseases including multiple myeloma (MM) and chronic lymphocytic 
leukaemia (CLL). WM treatment guidelines have been published by the BCSH and the European 
Society for Medical Oncology (ESMO) [9, 10]. Both guidelines recognise the lack of randomised 
evidence for WM treatments, especially as part of combination therapy. For first-line treatment of 
medically fit patients, both guidelines advocate rituximab in combination with chemotherapy, with the 
GHIHUUDORIULWX[LPDELQFDVHVRI³,J0IODUH´. Both guidelines reject the use of rituximab as maintenance 
therapy due to limited evidence. For medically fit patients with relapsed or refractory (R/R) disease, 
guidelines advocate continuing with rituximab and chemotherapy combination therapy, albeit using a 
different regimen from that given as first-line treatment [9, 10]. For many patients of advancing age and 
frailty there are very few effective options, particularly for those with R/R disease. 
 
In October 2015, NICE issued a final scope to appraise the clinical effectiveness and cost-effectiveness 
of ibrutinib for WM [11]. The NICE scope defined two discrete populations: (i) adults with WM who 
have received at least one prior therapy; (ii) adults with WM who have not received prior therapy and 
for whom chemo-immunotherapy is unsuitable. The comparators for ibrutinib within the previously 
treated population included rituximab in combination with chemotherapy (various regimens), and 
cladribine, chlorambucil and rituximab as monotherapies. For the untreated population in whom chemo-
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immunotherapy is unsuitable, the comparators included rituximab monotherapy, chlorambucil 
monotherapy and best supportive care (BSC). 
 
3. Independent ERG review 
The company (Janssen) provided a submission to NICE on the clinical effectiveness and cost 
effectiveness of ibrutinib for treating WM [8]. This submission was critically appraised by the ERG. 
Subsequently, the ERG identified areas requiring clarification, for which the company provided 
additional evidence prior to completion of the ERG report [12]. 
 
3.1 Clinical evidence submitted by the company 
The CS identified one relevant single-arm study ± Study 1118E [13]. In Study 1118E, 63 previously-
treated adult patients with WM from three sites in the USA were allocated to receive ibrutinib at a dose 
of 420mg/day. Treatment was administered for a median of 19.1 months (range 0.5 to 29.7 months) and 
43/63 patients (68%) remained on treatment after the final data cut-off (DCO) of 19th December 2014. 
The median age was 63.0 years (mean age = 64.5 years). Most (76.2%) patients were male. Median 
time from diagnosis of WM to study entry was 76 months (range: 6 to 340 months). The median number 
of prior regimens was 2 (range: 1 to 9 regimens).  
 
The principal efficacy outcomes were response and progression-free survival (PFS). The reported 
overall response rate (ORR, any response) was 90.5% (95% confidence interval [CI] 80.4% to 96.4%), 
which was achieved by 57/63 patients. Responders were categorised as follows: very good partial 
response (VGPR): n=10; partial response (PR): n=36; and minor response: n=11. The major response 
rate (defined as PR or better) was 73% (95% CI 60.3% to 83.4%). Based on data from the clinical study 
report (CSR), the Kaplan-Meier estimate for the event-free rate for all responders at 18 months was 
80.9% (95% CI  64.9% to 90.2%), and the corresponding estimate for major responders was 86.7% 
(95% CI  67.9% to 94.9%) [14]. The CS reported that subgroup analyses of ORR and major response 
rate were consistent across most subgroups (e.g. by age, Eastern Cooperative Oncology Group [ECOG] 
score at baseline, IPSSWM risk score) [8]. The Kaplan-Meier estimate of the PFS probability at 24 
months was 69.1% (95% CI 53.2% to 80.5%). At the 19th December 2014 DCO, 60 of the 63 patients 
were still alive and the estimated OS probability was 95.2% (95% CI 86% to 98.4%). Treatment with 
ibrutinib resulted in a significant decline in median percentage of bone marrow infiltration from 60% 
to 25% (p<0.001). There was insufficient evidence of a correlation between serum IgM levels and bone 
marrow involvement at 6 months (r=0.03, p=0.83), but there was evidence at 12 months (r=0.51, 
p<0.001) and at 24 months (r=0.56, p<0.008). At baseline, adenopathy and splenomegaly were 
identified by computed tomography (CT) in 37/63 (59%) and 7/63 (11%) patients, respectively, and the 
number of patients with lymphadenopathy and splenomegaly were reduced after ibrutinib treatment. 
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Given the absence of randomised head-to-head evidence comparing ibrutinib versus any other WM 
treatment, the CS presented an indirect comparison using PFS data from Study 1118E [13] and a 
matched cohort from a retrospective European Chart Review (ECR) [15]. 7KHFRPSDQ\¶VPXOWLYDULDEOH
Cox model produced an estimated hazard ratio (HR) for PFS for ibrutinib versus standard therapies of 
0.25 (95% CI 0.11 to 0.57). The use of alternative imputation methods produced more favourable HRs 
for PFS ranging from 0.19 to 0.22. 
 
The CS reported safety data from Study 1118E [13] together with additional results from selected 
supplementary studies in which patients with CLL or mantle cell lymphoma (MCL) received ibrutinib 
[16-20]. Within Study 1118E and the supplementary studies, the majority of adverse events (AEs) were 
mild to moderate in severity. The incidence of Grade 3/4 AEs was 49% in Study 1118E. The 
discontinuation rate following a median treatment duration of 19.1 months was 9.5%. 
 
The CS identified one ongoing study of ibrutinib in WM - PCYC-1127-CA (iNNOVATE - 
ClinicalTrials.gov Identifier NCT02165397). This is an international multi-centre, Phase III trial 
evaluating the safety and efficacy of ibrutinib in combination with rituximab in patients with WM, 
which includes a third arm of ibrutinib monotherapy, an open-label sub-study for 31 patients who are 
refractory to rituximab. Results from this study were not available at the time of the appraisal; the 
estimated study completion date is January 2019.  
 
3.2 Critique of clinical effectiveness evidence and interpretation 
7KH (5* FRQVLGHUHG WKH FRPSDQ\¶V reviews of clinical efficacy and safety evidence to be poorly 
reported and noted a lack of high quality evidence. There were no randomised controlled trials (RCTs) 
or non-randomised controlled trials of ibrutinib in the relevant populations listed in the NICE scope 
[11]. The clinical evidence consisted of one Phase II, single-arm, open-label study of ibrutinib in adult 
patients with WM who had received at least one prior therapy [13]. No evidence was available for 
ibrutinib in treatment-naïve patients with WM who are unsuitable for chemo-immunotherapy. 
 
The ERG noted several concerns regarding Study 1118E [13]. Whilst the study was generally well-
reported, it was at high risk of selection, performance and other bias, not only on account of its study 
design but also because of inadequate reporting of outcome measurement. The study included only 63 
patients, who were generally younger and had less severe disease than the R/R adults with WM who 
might routinely present in practice in England. The outcome measures used were generally valid and 
UHOLDEOHEXWWKHUHVSRQVHFULWHULDWKHSULPDU\RXWFRPHZHUH³PRGLILHG´IURPLQWHUQDWLonal standards 
[21]. With the exception of complete response (CR), the definitions of minor response, PR and VGPR 
applied in Study 1118E, as reported in the CS and protocols, differed from internationally recognised 
response criteria: in Study 1118E, they are limited to serum IgM level only, whilst international 
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standards also require the presence or absence of clinically significant findings or symptoms. The ERG 
noted that IgM response alone is insufficient as an outcome for WM because clinical benefit might be 
seen in patients without IgM response, or IgM reduction might not see an improvement of symptoms. 
Whilst response rates were consistent across most subgroups, differences in major response were 
particularly apparent for patients with different levels of ß2±microglobulin, haemoglobin, bone marrow 
disease involvement and genotype MYD88L265P and CXCR4WT. 
 
The ERG noted that AEs of any grade were very frequent in all studies included in the CS, with up to 
100% of patients in any of the included studies experiencing at least one AE and between 42% and 57% 
experiencing the most frequent event - diarrhoea [8].  
 
The ERG also had concerns regarding the reliability of the FRPSDQ\¶VLQGLUHFWFRPSDULVRQ, in particular 
due to: (i) the potential for unadjusted confounders; (ii) the lack of a unique matched sample from the 
ECR [15] and (iii) the exclusion of patients who had received five or more prior lines of treatment. In 
addition, the CS did not include an analysis of the relative survival impact of ibrutinib versus standard 
therapies for WM. 
 
3.3 Cost-effectiveness evidence submitted by the company 
7KHFRPSDQ\¶Vhealth economic model adopted a sequence-based Markov approach to estimate the 
health outcomes and costs for ibrutinib versus rituximab/chemotherapy for patients with R/R WM from 
the perspective of the NHS and Personal Social Services (PSS) over a 30-year (lifetime) horizon. The 
model included five health states: (1) second-line progression-free; (2) third-line progression-free; (3) 
fourth-line progression-free; (4) BSC and (5) dead. The model used parametric curves fitted to data on 
PFS, time to progression, pre-progression mortality and post-progression survival to inform transition 
rates between the health states. Transitions between states were modelled using a 28-day cycle length. 
Patients entered the model in the second-line progression-free state and received treatment with 
ibrutinib or rituximab/chemotherapy. Within the ibrutinib group, the probability of being progression-
free at any time t was modelled using a parametric (Weibull) survivor function fitted to the PFS time-
to-event data from Study 1118E [13]. Within the ibrutinib group, the probability that a patient leaving 
the second-line progression-free state dies was modelled using age- and sex-adjusted general population 
mortality hazards derived from life tables [22]. Within the rituximab/chemotherapy group, PFS in 
second-line was modelled using the inverse of the HR derived from the multivariable Cox model applied 
to the ibrutinib PFS curve [8], whilst the probability that a patient leaving the second-line progression-
free state dies was modelled using data derived from the matched ECR cohort [15]. Within both 
treatment groups, progression events in the third- and fourth-line progression-free states were estimated 
using data from the ECR for patients who were starting fourth-line treatment, whilst the probability of 
death in all post-second-line progression-free states was based on data from the ECR for patients who 
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had progressed from third-line treatment. A proportion of patients were assumed to transit directly to 
BSC after progressing from each line of therapy. HRQoL was differentiated according to the 
presence/absence of disease progression; owing to a lack of evidence, health utilities were based on 
EQ-5D-5L data collected within the RESONATE study of ibrutinib in R/R CLL and other literature 
[23]. Disutilities associated with AEs were included only for second-line treatment, based on published 
health valuation studies relating to CLL states [23, 24] and additional assumptions [8]; AEs associated 
with subsequent-line treatments were not included in the model. The model included costs associated 
with: (i) drug acquisition; (ii) drug administration (applied to the rituximab/chemotherapy regimens 
only); (iii) routine follow-up; (iv) the management of AEs; (v) BSC and (vi) terminal care. Resource 
use and cost estimates were drawn from the British National Formulary (BNF) [25], NHS Reference 
Costs 2014/15 [26], published literature [27] and expert opinion [8]. 7KHFRPSDQ\¶VDQDO\VLVincluded 
a Patient Access Scheme (PAS) for ibrutinib which took the form of a simple price discount. The value 
of this discount changed throughout the course of the appraisal. The level of the PAS is confidential; 
all cost-effectiveness results presented here are based on the original PAS. 
 
Based on a re-UXQ RI WKHSUREDELOLVWLF YHUVLRQ RI WKH FRPSDQ\¶V EDVH FDVH PRGHO E\ WKH (5*, the 
incremental cost-effectiveness ratio (ICER) for ibrutinib (including the original PAS) versus 
rituximab/chemotherapy was expected to be £58,905 per quality-adjusted life year (QALY) gained 
(deterministic ICER = £58,630 per QALY gained). Assuming a willingness-to-pay (WTP) threshold of 
£30,000 per QALY gained, the coPSDQ\¶V base case model suggested that the probability that ibrutinib 
produces more net benefit than rituximab/chemotherapy was approximately zero. Within the FRPSDQ\¶V
deterministic sensitivity analyses (DSAs) and scenario analyses, the ICER for ibrutinib versus 
rituximab/chemotherapy was consistently greater than £47,000 per QALY gained. The CS did not make 
DFDVHWKDWLEUXWLQLEVDWLVILHV1,&(¶V(QGRI/LIHFULWHULD, but did request that ibrutinib be listed on the 
Cancer Drugs Fund (CDF) within the WM indication. 
 
3.3.1 Critique of cost-effectiveness evidence and interpretation 
7KH(5*FULWLFDOO\DSSUDLVHGWKHFRPSDQ\¶VHFRQRPLFDQDO\VLVDQGpartially double-programmed the 
FRPSDQ\¶VPRGHO7KHPDLQLVVXHVLGHQWLILHGE\WKH(5*DUHGLVFXVVHGEHORZWKHIXOOFULWLTue can be 
found in the ERG report and the accompanying addendum [2, 28]. 
 
3.3.1.1 Absence of any economic analysis of ibrutinib in the first-line (treatment-naïve) setting  
The FRPSDQ\¶VPRGHOUHODWHG to patients who have received previous treatment for WM. The company 
did not present any evidence relating to the clinical effectiveness or cost-effectiveness of ibrutinib in 
treatment-naïve patients for whom chemo-immunotherapy is unsuitable. Therefore, the scope of the 
economic analysis was narrower than the marketing authorisation for ibrutinib in the WM indication. 
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3.3.1.2 &RQFHUQVUHJDUGLQJWKHFRPSDQ\¶VPRGHOOLQJDSSURDFK 
(i) Disconnect between the evidence and the model 
The coPSDQ\¶VPRGHOVWUXFWXUHLQFOXGHG three progression-free health states in which active treatment 
was assumed to be used (second-, third- and fourth-line therapy). All patients entered the model in the 
second-line progression-free state. However, this is inconsistent with the evidence used to inform the 
baseline PFS curve for ibrutinib and the evidence used to inform the indirect comparison. Within the 
VXEVHWRISDWLHQWVIURP6WXG\(ZKRZHUHLQFOXGHGLQWKHFRPSDQ\¶VPDWFKLQJH[HUFLVHXVHGWR
generate the treatment effect for ibrutinib (n=47), the majority of patients had received two or more 
prior lines of therapy (up to a maximum of four prior lines) [8]. Similarly, the matched cohort from the 
ECR (n=175) had received a median of two prior lines of therapy (range 1-4 lines). Consequently, the 
baseline risk of PFS and the treatment effects estimated from the Cox model do not correspond to the 
PRGHO¶Vsecond-line progression-free health state. Whilst the way that this evidence was used in the 
model implies that the number of prior lines of therapy received is not a treatment effect modifier, the 
progression rates for the third- and fourth-line progression-free health states applied in the model 
differed from those used for second-line progression-free health state. The ERG also noted that the 
evidence used to inform progression and death event rates throughout the subsequent states of the model 
was inconsistent with the definition of modelled health states (see Table 1).  
 
Table 1: Summary of evidence used to inform progression and death event rates by line of therapy 
[INSERT TABLE 1 HERE] 
 
(ii) Approach to modelling competing risks of progression and pre-progression death 
Pre-progression mortality in the second-line progression-free state was modelled conditional on PFS: 
the PFS curve determines the probability of leaving the state, whilst the pre-progression mortality curve 
determines the proportion of those patients leaving the state who transit to the dead state. This meant 
that within the ibrutinib group, the estimated contribution of PFS to overall survival would always be 
the same irrespective of the pre-progression mortality rate assumed in that state. As such, the pre-
progression mortality curve was entirely independent of survival gains accrued in the second-line 
progression-free state and impacted only upon survival gains accrued in subsequent-line states. This 
approach does not appropriately consider competing risks of progression and death and meant that 
changing these input parameters produced counter-intuitive model results. Given the underlying 
Markov structure adopted within the model, the ERG considered that the most appropriate approach 
would involve the independent modelling of time to progression (censoring for death) and pre-
progression mortality (censoring for progression) in order to properly account for competing risks. 
However, this would have required the re-estimation of treatment effects on progression and/or pre-
progression death separately. 
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(iii) Structural assumption of constant mortality hazard in third- and fourth-line progression-free states 
The cRPSDQ\¶V 0DUNRY approach imposed a structural assumption whereby survival following 
progression on second-line treatment must follow an exponential distribution. This was due to the use 
RIPXOWLSOHLQWHUPHGLDWHKHDOWKVWDWHVZLWKLQWKHFRPSDQ\¶VPRGHOWKLUG-line progression-free, fourth-
line progression-free and BSC). Whilst it would have been possible to apply time-variant event rates 
through the use of a semi-Markov design (using multiple tunnel states for incident patients entering 
each intermediate state during each cycle), or through the use of patient-level simulation, this was not 
SRVVLEOHZLWKLQWKHFRPSDQ\¶Vimplemented model. In response to a request for clarification from the 
ERG, the company provided additional analyses of pre-progression mortality data for patients receiving 
third-/fourth-line treatment; these analyses indicated that the exponential function provided a worse fit 
relative to the other models assessed. 
 
3.3.1.3 Potentially inappropriate data used to inform pre-progression mortality for 
rituximab/chemotherapy  
Given its structure, the model should have used a pre-progression mortality function, whereby only 
deaths occurring prior to progression are counted as events, and deaths occurring after progression are 
censored. The ERG had concerns that the data from the ECR [15], which were used to model pre-
progression mortality for the rituximab/chemotherapy group, may actually reflect overall survival 
(including all deaths). 7KLVFRQFHUQZDVUDLVHGEHFDXVHWKHUHOHYDQWILJXUHLQWKH&6ZDVODEHOOHG³7LPH
WR'HDWK´ [8]. Following the clarification process, the company stated that the figure contained in the 
CS reflected pre-progression mortality and also provided the Kaplan-Meier curve for OS from the ECR 
[15]. However, the two curves appeared to reflect the same data; this suggested that either the CS or the 
FRPSDQ\¶VFODULILFDWLRQUHVSRQse was inaccurate; hence, it remains unclear whether the model uses data 
on all deaths or only those occurring before progression to model pre-progression mortality for the 
rituximab/chemotherapy group. If OS data were used in the model in error, mortality in the comparator 
group would be artificially inflated and the ICER for ibrutinib could be significantly higher than the 
model suggested.  
 
3.3.1.4 Questionable assumption of general population mortality rates for ibrutinib patients in the 
second-line progression-free state 
The company¶Vmodel assumed that pre-progression mortality for patients receiving ibrutinib reflected 
mortality rates in the general population; this assumption was made because only three patients died 
within the 24-month follow-up period within Study 1118E [13]. The ERG noted that the observed death 
rate within Study 1118E is higher than that for the age- and sex-matched general population. This 
suggests that thHFRPSDQ\¶VPRGHOXQGHUHVWLPDWHV the pre-progression mortality rate for the ibrutinib 
group. 
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3.3.1.5 Limited clinical evidence available for ibrutinib versus rituximab/chemotherapy 
The ERG highlighted that there is an absence of head-to-head RCTs comparing ibrutinib versus any 
other therapy, and that WKHFRPSDQ\¶VDGMXVWHGDUP-based indirect comparison is subject to weaknesses 
and uncertainties. In addition, Study 1118E recruited only a small patient population (n=63) and the 
analysis at DCO 19th December 2014 included only three deaths, all of which occurred prior to disease 
progression. Furthermore, Study 1118E did not include the use of a preference-based measure of 
HRQoL and no other HRQoL studies in WM were identified from the literature. As a consequence of 
these issues, the ERG considered that any estimate of the relative benefits of ibrutinib on PFS, OS and 
HRQoL should be considered highly uncertain and that the results of the company¶VHFRQRPLFDQDO\VLV
were largely speculative. 
 
3.3.1.6 Additional concerns  
The ERG identified several additional issues UHJDUGLQJWKHFRPSDQ\¶VPRGHO; these related to: (i) the 
FRPSDQ\¶V SDUDPHWULF VXUYLYDO PRGHOOLQJ DQG PRGHO VHOHFWLRQ procedures; (ii) the use of separate 
evidence sources to inform the health gains and costs associated with rituximab/chemotherapy; (iii) the 
use of a blended comparator; (iv) concerns regarding health utilities assumed within the model; (v) 
errors and discrepancies relating to drug acquisition costs for rituximab/chemotherapy, and (vi) the 
incomplete representation of uncertainty. These issues are discussed in detail in the ERG report [2]. 
 
3.4 Additional work undertaken by the ERG 
The ERG undertook 10 sets of exploratory analyses. These analyses explored the impact of correcting 
the drug acquisition and follow-up costs, the use of alternative PFS treatment effect estimates, the use 
of observed pre-progression mortality rates for ibrutinib from Study 1118E, the removal of all assumed 
survival gains, the use of a Weibull distribution for pre-progression mortality in the 
rituximab/chemotherapy group, and the use of alternative utility values for the BSC state. In addition, 
the ERG undertook a threshold analysis in which the HR for PFS was varied from 0.01 to 1.0. The 
(5*¶VSUHIHUUHGDQDO\VLV included the re-estimation of drug acquisition costs, the correction of errors 
in the follow-up costs and the use of observed pre-progression mortality data from Study 1118E. This 
analysis generated a probabilistic ICER of £61,219 per QALY gained (Table 2). Based on this ERG-
preferred model, the subsequent exploratory analyses produced ICERs for ibrutinib which were greater 
than £60,000 per QALY gained. The most extreme scenario, which assumed no additional survival gain 
for ibrutinib, produced an ICER of £390,432 per QALY gained. The (5*¶V threshold analysis 
suggested that irrespective of the HR for PFS, the ICER for ibrutinib versus rituximab/chemotherapy 
was at least £56,917 per QALY gained (Figure 1). 
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Table 2: Summary of key results from the CS and the ERG report (using the original PAS for 
ibrutinib in the WM indication)  
[INSERT TABLE 2 HERE] 
 
Figure 1: ERG exploratory analysis 10 - threshold analysis around HR for PFS (using the original 
PAS for ibrutinib in the WM indication)  
[INSERT FIGURE 1 HERE] 
 
3.5 Conclusion of the ERG report 
The absence of any head-to-head RCT evidence for ibrutinib versus standard therapies and concerns 
UHJDUGLQJ WKH FRPSDQ\¶V DGMXVWHG DUP-based indirect comparison result in considerable uncertainty 
surrounding the clinical benefits of ibrutinib for the treatment of WM. Given the weaknesses in the 
FRPSDQ\¶V PRGHO DQG WKH HYLGHQFH XVHG WR LQIRUP LW WKH WUXH ,&(5 IRU LEUXWLQLE YHUVXV
rituximab/chemotherapy remains unclear. Notwithstanding this uncertainty, (5*¶V H[SORUDWRU\
threshold analyses suggested that even under the FRPSDQ\¶V optimistic assumption of general 
population mortality rates whilst patients are receiving ibrutinib, the ICER for ibrutinib versus rituximab 
is not expected to be below £56,917 per QALY gained, irrespective of the HR for PFS. Other things 
being equal, this represents a best-case scenario for the cost-effectiveness of ibrutinib versus 
rituximab/chemotherapy in the R/R WM setting. Given the highly favourable assumptions regarding 
OS benefits employed in the FRPSDQ\¶V model, the ERG considered it unlikely that further data 
collection on PFS and OS outcomes for patients receiving ibrutinib would lead to more favourable cost-
effectiveness estimates. 
 
4. Methodological issues 
The principal uncertainty relates to the absence of any head-to-head randomised evidence through 
which to estimate the benefits of ibrutinib on clinically meaningful outcomes, and the potential for bias 
and confounding in the FRPSDQ\¶V LQGLUHFW FRPSDULVRQ RI 3)6 RXWFRPHV. Alongside these clinical 
XQFHUWDLQWLHVWKHFRPSDQ\¶VPRGHOZDVVXEMHFWWRVWUXFWXUDODQGLPSOHPHQWDWLRQLVVXHV which limit the 
reliability of the results. 
 
5. National Institute for Health and Care Excellence (NICE) guidance 
The AC reviewed the data available on the clinical and cost effectiveness of ibrutinib, having considered 
evidence on the nature of WM and the value placed on the benefits of ibrutinib by people with the 
condition, those who represent them, and clinical experts. It also took into account the effective use of 
NHS resources. 
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The ACD (published October 2016) stated that ibrutinib was not recommended within its marketing 
authorisation for treating WM in adults who have had at least one prior therapy or as first-line treatment 
when chemo-immunotherapy is unsuitable. The AC noted that the FRPSDQ\¶VEDVHFDVHICER was well 
above the level which could be accepted as a cost-effective use of NHS resources, and that whilst the 
company had requested that ibrutinib be referred to the CDF, it did not have the plausible potential for 
satisfying the criteria for routine use. 
 
In response to the ACD, the company submitted a revised version of the model which included five 
amendments:  
(1) The survivor function for PFS for the ibrutinib group was replaced with data relating to the 12th 
December 2014 DCO of Study 1118E. 
(2) Pre-progression mortality in the ibrutinib group was modelled using an exponential survivor 
function derived from Study 1118E, which was capped at the level of general population 
mortality. 
(3) Pre-progression mortality in the rituximab/chemotherapy group was modelled using an 
alternative survivor function derived from a re-analysis of the ECR.  
(4) Chemotherapy drug cost calculations were amended.  
(5) The PAS for ibrutinib was updated. 
 
7KH(5*QRWHGWKDWWKHFRPSDQ\¶VUHYLVHGPRGHOGLGQRWDGGUHVVDOORIWKHLVVXHVUDLVHGZLWKLQWKH
ERG report [2]. Despite the company providing additional explanation, the ERG remained unclear 
whether the pre-progression mortality function in the rituximab/chemotherapy group had been 
generated appropriately and noted that this aspect of the model had the propensity to dramatically 
increase the ICER for ibrutinib versus rituximab/chemotherapy, as previously shown in the (5*¶V
exploratory analyses. 
 
Following the second AC meeting, the company proposed an improved commercial offer for the use of 
ibrutinib in the WM indication in the CDF. In September 2017, NICE published its FAD, which made 
the following recommendation: ³Ibrutinib is recommended, within its marketing authorisation, for use 
in the CDF as an option for treating :DOGHQVWU|P¶V macroglobulinaemia in adults who have had at 
least 1 prior therapy or as first-line treatment when chemo-immunotherapy is unsuitable, only if the 
conditions in the managed access agreement for ibrutinib are followed´ [3]. 
 
5.1 Consideration of clinical effectiveness and cost-effectiveness issues 
This section discusses the key issues considered by the AC. The full list can be found in the FAD [3]. 
 
5.1.1 Clinical trial evidence 
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The committee noted that the clinical evidence for ibrutinib came from one single-arm, open-label study 
and that Study 1118E was generally well reported. The committee noted that there were several 
potential biases resulting from the use of an open-label study design. The committee concluded that 
Study 1118E is of a reasonable quality, is generalisable to UK clinical practice and is suitable for 
decision-making, but is limited by the lack of a comparison against a treatment used in the UK. The AC 
concluded that the longer-term effects of ibrutinib on progression and survival are uncertain because no 
data are available. The committee understood that no clinical trial evidence had been presented for WM 
in adults who have not had prior therapy and for whom chemo-immunotherapy is unsuitable. 
 
5.1.2 Indirect comparison 
The committee understood WKDWWKHFRPSDQ\¶VLQGLUHFWFRPSDULVRQVXJJHVWHGDVXEVWDQWLDOUHGXFWLRQLQ
the risk of disease progression with ibrutinib compared with existing WM therapies. The committee 
was aware that the ERG had several FRQFHUQVZLWKWKHFRPSDQ\¶VDSSURDFK, including the methods 
used to select patients in the matched cohort. Based on the results of the indirect comparison and the 
testimonies from patients and clinical experts, the committee accepted that ibrutinib appears to be more 
clinically effective than existing treatments, but concluded that there is considerable uncertainty about 
the size of the long-term benefit because of limitations in the available data. 
 
&RPSDQ\¶VHFRQRPLFPRGHO structure 
The committee noted that the company had developed a Markov model comparing ibrutinib with 
WUHDWPHQW RI SK\VLFLDQ¶V FKRLFH for patients with R/R WM who had had one prior therapy. The 
committee heard from the ERG that many patients in Study 1118E had more than one prior therapy and 
WKDWWKHVHTXHQFLQJXVHGLQWKHFRPSDQ\¶VPRGHOZDVLQFRQVLVWHQWZLWKWKHGDWDDQGSRSXODWLRQLQthe 
clinical study. The committee concluded that the model structure was acceptable for decision-making 
but was mindful of its limitations. 
 
5.1.4 Uncertainties around plausibility of assumptions and inputs in the economic model 
The committee considered the estimates of pre-progression mortality and accepted that there is 
uncertainty because of limitations in the data available. The committee QRWHGWKH(5*¶VFRPPHQWVWKDW
the company had potentially used unsuitable data to inform the pre-progression mortality for the 
comparator group. The committee noted that, in response to consultation, the company had revised its 
approach to modelling pre-progression mortality for the comparator group but the committee heard 
from the ERG that some uncertainty remained about whether there was an inflated risk of death prior 
to progression in the comparator group. However, the committee noted that the cost-effectiveness 
estimates were not sensitive to changes in pre-progression mortality for the comparator group and 
FRQFOXGHGWKDWWKHFRPSDQ\¶VUHYised approach was acceptable for decision-making (although the ERG 
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notes that the true impact of this issue remains unclear due to ongoing ambiguity regarding which data 
were used to model pre-progression mortality). 
 
7KHFRPPLWWHHQRWHGWKDWWKHFRPSDQ\¶V original model had assumed general population mortality rates 
for pre-progression mortality in ibrutinib arm. The committee was aware that the company had revised 
its modelling approach, LQUHVSRQVHWRWKH(5*¶VFRQFHUQVUHSRUWHGLQWKHACD, to assume a constant 
hazard based on Study 1118E data until the constant hazard crossed the general population hazard, 
when the general population hazard was assumed. 7KH FRPPLWWHH FRQFOXGHG WKDW WKH FRPSDQ\¶V
DSSURDFKZDVOLNHO\WRUHSUHVHQWDµEHVWFDVH¶VFHQDULRDQG that a less favourable mortality rate would 
OHDGWRDKLJKHU,&(5WKDQWKHRQHSUHVHQWHGLQWKHFRPSDQ\¶VEDVHFDVH 
 
5.1.5 Most plausible ICER 
7KHFRPPLWWHHQRWHGWKDWWKHFRPSDQ\¶VEDVH-case ICER incorporating the updated PAS for ibrutinib 
and revisions to the model was £54,100 per QALY gained. The committee recalled its earlier 
conclusions that there is uncertainty about the size of the clinical benefit of ibrutinib compared with 
existing WM therapies and in the modelling of pre-progression mortality. The committee heard from 
the ERG that their amended base-case ICER (including re-estimating drug acquisition and 
administration costs, correcting errors on follow-up costs and using pre-progression mortality data from 
PCYC-1118E) was between £56,000 and £57,000 per QALY gained when incorporating the updated 
PAS. The committee concluded that this was substantially above the range normally considered a cost-
effective use of NHS resources (that is, between £20,000 and £30,000 per QALY gained).  
 
5.1.6 Cancer Drugs Fund 
Given that the uncertainty in the clinical and cost-effectiveness data was too great to recommend 
ibrutinib for routine use, the committee considered whether it would be appropriate to recommend 
ibrutinib for inclusion in the CDF. The committee can consider a recommendation for use within CDF 
if it is possible that the clinical uncertainty can be addressed through collection of outcomes data from 
patients treated in the NHS and, if the ICERs presented have the plausible potential to be cost-effective.  
 
The committee considered what additional data could be collected to resolve some of the clinical 
uncertainties it had highlighted. The committee expressed interest in seeing updated efficacy data from 
the iNNOVATE trial and Study 1118E. The committee agreed that uncertainty in pre-progression 
mortality for those receiving ibrutinib could be addressed by collecting overall survival data using the 
Systemic Anti-Cancer Therapy dataset. The committee understood that the company intended to add-
on to an existing national registry of people with WM to collect additional efficacy and resource use 
data. The committee heard from the clinical experts that the national registry includes over 300 patients 
and can record patient-level data (on progression, survival, response, quality of life, and genomic 
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markers). The committee considered that these data would be a valuable addition to the clinical evidence 
base and may resolve some of the uncertainties identified.  
 
The committee heard from the company that it had made an offer to provide ibrutinib at a price that 
resulted in ibrutinib being cost-effective within the CDF. The committee also heard that the company 
was committed to exploring mechanisms for providing ibrutinib at a cost-effective price when it is re-
appraised by NICE upon its exit from the CDF. The committee concluded that it would be able to 
recommend ibrutinib as an option for use within the CDF for treating WM provided that a managed 
access agreement was in place that allowed ibrutinib to be used cost-effectively within the CDF. 
 
6. Appraisal committee¶Vkey conclusion 
The committee considered that the most plausible ICER is likely to be at least £54,100 per QALY 
gained and noted that this is substantially above the level considered to be a cost-effective use of NHS 
resources. However, the committee concluded that it would be able to recommend ibrutinib as an option 
for use within the CDF for treating WM provided that a managed access agreement was in place that 
allowed ibrutinib to be used cost-effectively within the CDF. 
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Table 1: Summary of evidence used to inform progression and death event rates by line of therapy 
Model 
health state 
Progression Death 
Ibrutinib  Rituximab/chemotherapy Ibrutinib  Rituximab/chemotherapy 
Second-line 
progression-
free 
Full population from 
Study 1118E (1-9 prior 
treatments).  
 
ERG comment 
Patients in the model by 
definition have only 
received one prior line of 
therapy on entry 
Patients who had received 
between 1 and 4 prior lines of 
therapy in the ECR.  
 
ERG comment 
Patients in the model by 
definition have only received 
one prior line of therapy on 
entry 
Based on life tables. Patients receiving second-, third- or 
fourth-line therapy in the ECR.  
 
ERG comment 
Patients in the model by definition have 
only received one prior line of therapy on 
entry 
Third-line 
progression-
free 
Patients starting fourth-line treatment in the ECR.  
 
ERG comment 
Patients in the model are by definition starting third-line 
treatment 
Patients progressed from third-line treatment in the ECR.  
 
ERG comment 
Patients in the model are by definition progression-free in third-line 
Fourth-line 
progression-
free 
Patients starting fourth-line treatment in the ECR.  
 
ERG comment 
Evidence consistent with model 
Patients progressed from third-line treatment in the ECR.  
 
ERG comment 
Evidence consistent with model 
BSC Not applicable 
 
Patients progressed from third-line treatment in the ECR.  
 
ERG comment 
Includes post-progression survival outcomes for patients receiving active 
therapy rather than BSC 
BSC ± best supportive care; ERG ± Evidence Review Group; ECR ± European Chart Review 
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Figure 1: ERG exploratory analysis 10 - threshold analysis around HR for PFS (using the original PAS for ibrutinib in the WM indication). ICER 
incremental cost-effectiveness ratio, HR hazard ratio, PFS progression-free survival 
 
